The age gap between patients in clinical studies and in the general population: a pitfall for dementia research

Lancet Neurology
Niels Schoenmaker, Willem A Van Gool

Abstract

The growing global disease burden attributable to dementia has strongly stimulated research activities. However, patients with dementia that are included in clinical research are systematically younger than patients from the general population. This large age gap perhaps indicates a lack of methodological rigour, but, more importantly, has the potential to affect the interpretation of research finding-eg, those relating to neuropathology, apolipoprotein E polymorphisms, the effects of cholinesterase inhibitors, and many other issues relevant to patients with dementia. Research on dementia has a lot to gain from the study of patients that more appropriately reflect the population at risk.

References

Jan 15, 2003·Neurology·A S RigaudUNKNOWN French Study Group
Apr 4, 2003·The New England Journal of Medicine·Barry ReisbergUNKNOWN Memantine Study Group
Apr 12, 2003·Neurology·O M WolkowitzUNKNOWN DHEA-Alzheimer's Disease Collaborative Research
May 20, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·P M KempJ S Fleming
Jun 10, 2003·Alzheimer Disease and Associated Disorders·Anders WimoEva von Strauss

❮ Previous
Next ❯

Citations

May 29, 2009·The New England Journal of Medicine·George M SavvaUNKNOWN Medical Research Council Cognitive Function and Ageing Study
Aug 26, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ugo LuccaAngela Recchia
May 2, 2007·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·David B Hogan
Jan 29, 2016·Journal of Biomedical Informatics·Zhe HeChunhua Weng
Nov 2, 2006·Current Medical Research and Opinion·Serge GauthierUNKNOWN EXTEND Investigators
Apr 1, 2006·Current Medical Research and Opinion·Roger BullockRoger Lane
Oct 23, 2012·Lancet·Carol Brayne, Daniel Davis
Feb 19, 2008·La Presse médicale·Olivier Saint JeanCéline Lazarovici
Sep 3, 2011·Journal of the American Geriatrics Society·Ben SchmandUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Aug 4, 2015·Journal of the American Geriatrics Society·Meera SheffrinMichael A Steinman
Jan 1, 2013·Journal of Molecular Psychiatry·Smaranda Ioana MitranTudor-Adrian Balseanu
Jan 24, 2015·Journal of Biomedical Informatics·Zhe HeChunhua Weng
Aug 16, 2016·Alzheimer's Research & Therapy·Rita BanziUgo Lucca
Nov 10, 2015·Trends in Pharmacological Sciences·Chunhua Weng
Sep 7, 2016·Annals of the New York Academy of Sciences·Anando SenChunhua Weng
Dec 14, 2017·Health Technology Assessment : HTA·Frances BunnChris Burton
Aug 28, 2018·CNS Neuroscience & Therapeutics·Marco CanevelliMatteo Cesari
Jan 16, 2020·PloS One·E-Shien ChangBecca R Levy
Dec 2, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ugo LuccaAngela Recchia
Oct 13, 2017·Journal of the American Medical Informatics Association : JAMIA·Anando SenChunhua Weng
Jan 13, 2018·Dementia·Ruth BartlettRebecca Croucher
Jan 19, 2007·Journal of the American College of Nutrition·Mauro TettamantiUgo Lucca
May 8, 2018·Journal of Korean Medical Science·Eun-Ye LimA-Hyun Cho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.